Cyproterone acetate in the treatment of metastatic cancer of the male breast.
Ten male patients with advanced cancer of the breast were treated with cyproterone acetate, an anti-androgenic compound with additional progestational properties. Seven patients achieved a response, for a median duration of 8 months. Plasma testosterone and estradiol levels fell significantly during therapy, but quantitatively this drop was not related to the therapeutic response. Cyproterone acetate is an effective and well-tolerated treatment for metastatic male breast cancer.
D000368:Aged; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D003534:Cyproterone / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D007172:Erectile Dysfunction / Q000139:chemically induced; D004958:Estradiol / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D004958:Estradiol; D011388:Prolactin; D003534:Cyproterone